Jerrell Shelton Sells 28,800 Shares of CryoPort (NASDAQ:CYRX) Stock

Key Points

• CEO Jerrell Shelton sold 28,800 CryoPort shares for approximately $429,408 under a pre-arranged Rule 10b5-1 trading plan, reducing his direct holdings by 2.34% to 1,201,814 shares.
• CryoPort shares rose 0.9% to $14.95, while the company’s latest quarterly loss of $0.20 per share narrowly missed estimates; revenue of $48.97 million exceeded expectations.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $18.00; institutional investors own 92.9% of the company.

CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 28,800 shares of CryoPort stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $14.91, for a total value of $429,408.00. Following the sale, the chief executive officer directly owned 1,201,814 shares of the company's stock, valued at approximately $17,919,046.74. This trade represents a 2.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

CryoPort Trading Up 0.9%

Shares of CYRX traded up $0.13 during midday trading on Tuesday, reaching $14.95. The stock had a trading volume of 624,658 shares, compared to its average volume of 591,327. The company has a market capitalization of $757.20 million, a price-to-earnings ratio of -16.61 and a beta of 1.89. The company's 50-day moving average is $15.47 and its 200 day moving average is $11.95. CryoPort, Inc. has a 12-month low of $7.61 and a 12-month high of $16.89.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.01). The firm had revenue of $48.97 million for the quarter, compared to analysts' expectations of $48.18 million. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. Research analysts forecast that CryoPort, Inc. will post -0.85 EPS for the current fiscal year.

Analyst Ratings Changes

CYRX has been the subject of a number of research reports. Roth Capital reaffirmed a "buy" rating and issued a $21.00 price objective on shares of CryoPort in a research note on Friday. Craig Hallum boosted their price target on shares of CryoPort from $15.00 to $20.00 and gave the stock a "buy" rating in a research note on Wednesday, June 3rd. Needham & Company LLC upped their price target on shares of CryoPort from $15.00 to $19.00 and gave the company a "buy" rating in a research report on Friday. Wall Street Zen raised CryoPort from a "sell" rating to a "hold" rating in a research note on Monday, May 11th. Finally, BTIG Research lifted their price objective on CryoPort from $17.00 to $25.00 and gave the stock a "buy" rating in a report on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $18.00.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Basepoint Wealth LLC bought a new stake in CryoPort during the 4th quarter valued at $34,000. Tower Research Capital LLC TRC grew its holdings in CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after acquiring an additional 4,375 shares during the last quarter. Creative Planning bought a new stake in CryoPort in the 2nd quarter worth $96,000. Quadrature Capital Ltd purchased a new position in shares of CryoPort in the fourth quarter valued at about $97,000. Finally, State of Wyoming increased its position in shares of CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company's stock valued at $106,000 after acquiring an additional 3,301 shares during the period. Institutional investors own 92.90% of the company's stock.

About CryoPort

CryoPort, Inc NASDAQ: CYRX is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source